Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
cipla.com

See what CB Insights has to offer

Investments

5

Portfolio Exits

2

Partners & Customers

10

About Cipla

Cipla (BSE: 500087) (NSE: CIPLA) is a multinational pharmaceutical and biotechnology company. Cipla primarily develops medicines to treat cardiovascular disease, arthritis, diabetes, weight control, and depression, as well as other medical conditions.

Cipla Headquarter Location

Cipla House, Peninsula Business Park Ganpatrao Kadam Marg, Lower Parel

Mumbai, 400 013,

India

+91 22 23082891

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Cipla

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Cipla in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

11,639 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

D

Diabetes

1,750 items

Cipla Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Cipla Rank

Latest Cipla News

Cipla obtains FDA nod for generic Durezol

Sep 21, 2021

Durezol had a market value of approximately $106 million for the 12-month period ended June 2021, according to IQVIA. The medication is the generic of Novartis’ Durezol. It is used for the treatment of inflammation and pain associated with ocular surgery, and for the treatment of endogenous anterior uveitis.

Cipla Investments

5 Investments

Cipla has made 5 investments. Their latest investment was in IndoHealth Services as part of their Corporate Minority on March 3, 2021.

CBI Logo

Cipla Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/31/2021

Corporate Minority

IndoHealth Services

$5.46M

Yes

1

6/10/2020

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

2/18/2019

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

11/13/2018

Corporate Minority - P2P

Subscribe to see more

$99M

Subscribe to see more

10

Other Investors

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/31/2021

6/10/2020

2/18/2019

11/13/2018

Round

Corporate Minority

Corporate Minority

Corporate Minority

Corporate Minority - P2P

Other Investors

Company

IndoHealth Services

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$5.46M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

10

10

Cipla Portfolio Exits

2 Portfolio Exits

Cipla has 2 portfolio exits. Their latest portfolio exit was Cipla Vet on March 06, 2017.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/6/2017

Divestiture

2

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

3/6/2017

00/00/0000

Exit

Divestiture

Subscribe to see more

Companies

Subscribe to see more

Valuation

Acquirer

Subscribe to see more

Sources

2

10

Cipla Acquisitions

12 Acquisitions

Cipla acquired 12 companies. Their latest acquisition was Wanbury - CPink, CDense, Productiv, Folinine on February 10, 2020.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

2/10/2020

Acquired Unit

1

12/9/2019

Corporate Majority

Acquired

3

7/12/2018

$991

Acquired

4

4/1/2017

Subscribe to see more

$991

$99M

Subscribe to see more

10

9/4/2015

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/10/2020

12/9/2019

7/12/2018

4/1/2017

9/4/2015

Investment Stage

Corporate Majority

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Total Funding

$99M

$99M

Note

Acquired Unit

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

1

3

4

10

10

Cipla Partners & Customers

10 Partners and customers

Cipla has 10 strategic partners and customers. Cipla recently partnered with Eli Lilly and Company on May 5, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

5/10/2021

Licensor

Eli Lilly and Company

United States

India’s Cipla to make and sell Eli Lilly’s baricitinib to treat COVID-19

BENGALURU -- Indian drugmaker Cipla Ltd said on Monday it had entered into a licensing agreement with U.S. company Eli Lilly to make and sell Lilly 's arthritis drug baricitinib for the treatment of COVID-19 patients .

8

5/6/2021

Licensor

Roche Holding

Switzerland

Roche, Cipla to bring Casirivimab/Imdevimab Covid-19 drug to India

This partnership with Roche is a significant step in enabling access to promising treatments in furtherance to our purpose of ` Caring for Life ' . ''

1

4/28/2021

Licensor

MSD

United States

Cipla partners with MSD to manufacture and distribute Molnupiravir, drug to treat Covid-19

Cipla Limited partners with MSD to manufacture and distribute Molnupiravir , drug to treat Covid-19

1

3/23/2021

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

3/2/2021

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

5/10/2021

5/6/2021

4/28/2021

3/23/2021

3/2/2021

Type

Licensor

Licensor

Licensor

Partner

Licensor

Business Partner

Eli Lilly and Company

Roche Holding

MSD

Country

United States

Switzerland

United States

Subscribe to see more

Subscribe to see more

News Snippet

India’s Cipla to make and sell Eli Lilly’s baricitinib to treat COVID-19

BENGALURU -- Indian drugmaker Cipla Ltd said on Monday it had entered into a licensing agreement with U.S. company Eli Lilly to make and sell Lilly 's arthritis drug baricitinib for the treatment of COVID-19 patients .

Roche, Cipla to bring Casirivimab/Imdevimab Covid-19 drug to India

This partnership with Roche is a significant step in enabling access to promising treatments in furtherance to our purpose of ` Caring for Life ' . ''

Cipla partners with MSD to manufacture and distribute Molnupiravir, drug to treat Covid-19

Cipla Limited partners with MSD to manufacture and distribute Molnupiravir , drug to treat Covid-19

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

8

1

1

10

10

Cipla Team

4 Team Members

Cipla has 4 team members, including former Chief Financial Officer, Herman van Barneveld.

Name

Work History

Title

Status

Herman van Barneveld

Chief Financial Officer

Former

Narayan Saraf

PharmEasy, Unilever, and Oil and Natural Gas

Chief Financial Officer

Former

Debashis Sarkar

Chief Marketing Officer, Senior Vice President

Former

Sarabjit Singh

Senior Vice President

Former

Name

Herman van Barneveld

Narayan Saraf

Debashis Sarkar

Sarabjit Singh

Work History

PharmEasy, Unilever, and Oil and Natural Gas

Title

Chief Financial Officer

Chief Financial Officer

Chief Marketing Officer, Senior Vice President

Senior Vice President

Status

Former

Former

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.